SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
ESSA Pharma Inc. (EPIX) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+4621.7%).
- Analyst consensus target $9.50 (+4621.7% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 56/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — EPIX
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.64
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$9.50 (+4621.7%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-9.34 |
$0.00 |
$-8.57M |
- |
| 2016 |
$-9.77 |
$217.00 |
$-13.14M |
-6055299.5% |
| 2017 |
$-3.09 |
$0.00 |
$-4.5M |
- |
| 2018 |
$-2.55 |
$0.00 |
$-11.63M |
- |
| 2019 |
$-1.24 |
$0.00 |
$-10.44M |
- |
| 2020 |
$-1.04 |
$0.00 |
$-23.45M |
- |
| 2021 |
$-0.96 |
$0.00 |
$-36.81M |
- |
| 2022 |
$-0.80 |
$0.00 |
$-35.1M |
- |
| 2023 |
$-0.60 |
$0.00 |
$-26.58M |
- |
| 2024 |
$-0.64 |
$0.00 |
$-28.54M |
- |
